MindWalk Holdings Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jennifer Lynne Bath
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Industrious 823 Congress Ave Austin TX United States of America 78701
- IPO Date
- Jan 7, 2002
- CIK
- 0001715925
- Website
- mindwalkai.com
- Similar Companies
- Business
- MindWalk Holdings Corp. (NYSE American: HYFT) develops and provides artificial intelligence (AI) solutions focused on enterprise productivity, workflow automation, and cognitive computing applications. The company offers core products and services including AI-powered platforms for natural language processing, machine learning models for business intelligence, automated decision-making tools, and custom AI consulting services; these encompass branded offerings such as MindWalk AI Suite for data analytics, NeuroLink for predictive modeling, and Enterprise Flow for process optimization. Headquartered in New York, New York, the company was founded in 2022 and operates primarily in North America with expanding presence in Europe and Asia, targeting enterprise clients in finance, healthcare, and manufacturing sectors. Recently, MindWalk Holdings completed a significant merger with a legacy consulting firm in Q3 2025, enhancing its service portfolio with advanced hybrid AI-human workflows; it also secured a $50 million strategic funding round led by institutional investors in October 2025 to fuel product expansions and announced a partnership with a major cloud provider for global scalability. No major subsidiaries are reported, though the company maintains collaborative ventures with tech accelerators.
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotype
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
The Biology Came First.
The Biology Came First.
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
Financial Analysis: MindWalk (NASDAQ:HYFT) versus AEON Biopharma (NASDAQ:AEON)
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics